Results 11 to 20 of about 55,635 (283)

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies [PDF]

open access: goldMolecules, 2023
Targeting cancer cells that are highly dependent on the nicotinamide adenine dinucleotide (NAD+) metabolite is a promising therapeutic strategy. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme catalyzing NAD+ production ...
Paulina Biniecka   +16 more
doaj   +2 more sources

It takes two to tango: NAD+ and sirtuins in aging/longevity control [PDF]

open access: yes, 2016
The coupling of nicotinamide adenine dinucleotide (NAD+) breakdown and protein deacylation is a unique feature of the family of proteins called ‘sirtuins.’ This intimate connection between NAD+ and sirtuins has an ancient origin and provides a ...
Guarente, Leonard, Imai, Shin-ichiro
core   +2 more sources

Pyrroloquinoline quinone increases the expression and activity of Sirt1 and -3 genes in HepG2 cells. [PDF]

open access: yes, 2015
Sirtuin (Sirt) 1 and Sirt 3 are nicotinamide adenine dinucleotide ((+))-dependent protein deacetylases that are important to a number of mitochondrial-related functions; thus, identification of sirtuin activators is important. Herein, we hypothesize that
Arguelles, Andrix   +6 more
core   +1 more source

Crystalline Quinolinate Phosphoribosyltransferase

open access: yesJournal of Biological Chemistry, 1965
Abstract Quinolinate phosphoribosyltransferase catalyzes the formation of nicotinic acid mononucleotide, carbon dioxide, and inorganic pyrophosphate from quinolinic acid and 5-phosphoribosyl 1-pyrophosphate. The enzyme has a molecular weight of 165,000 and can be irreversibly dissociated into inactive protein units with a molecular weight of 54,000 ...
P M, Packman, W B, Jakoby
openaire   +2 more sources

The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells

open access: yesHaematologica, 2012
Background Inhibitors of nicotinamide phosphoribosyltransferase have recently been validated as therapeutic targets in leukemia, but the mechanism of leukemogenic transformation downstream of this enzyme is unclear.Design and Methods Here, we evaluated ...
Lan Dan   +7 more
doaj   +1 more source

SIRT1 selectively exerts the metabolic protective effects of hepatocyte nicotinamide phosphoribosyltransferase

open access: yesNature Communications, 2022
NAD + metabolism is potential target to treat metabolic disorders, in part due to the effects of the NAD + dependent enzyme Sirt1. Here the authors report that hepatic nicotinamide phosphoribosyltransferase, a rate-limiting step in the NAD + salvage ...
Cassandra B. Higgins   +6 more
doaj   +1 more source

Absolute quantification of the host-to-parasite DNA ratio in Theileria parva-infected lymphocyte cell lines [PDF]

open access: yes, 2016
Theileria parva is a tick-transmitted intracellular apicomplexan pathogen of cattle in sub-Saharan Africa that causes East Coast fever (ECF). ECF is an acute fatal disease that kills over one million cattle annually, imposing a tremendous burden on ...
Bishop, Richard P.   +5 more
core   +4 more sources

Identification of Fis1 Interactors in Toxoplasma gondii Reveals a Novel Protein Required for Peripheral Distribution of the Mitochondrion [PDF]

open access: yes, 2020
Toxoplasma gondii’s single mitochondrion is very dynamic and undergoes morphological changes throughout the parasite’s life cycle. During parasite division, the mitochondrion elongates, enters the daughter cells just prior to cytokinesis, and undergoes ...
Arrizabalaga, Gustavo   +2 more
core   +1 more source

PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse. [PDF]

open access: yesPLoS ONE, 2011
Lesch-Nyhan disease (LND) is a severe X-linked neurological disorder caused by a deficiency of hypoxanthine phosphoribosyltransferase (HPRT). In contrast, HPRT-deficiency in the mouse does not result in the profound phenotypes such as self-injurious ...
Alaine C Keebaugh   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy